Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
about
Uses, misuses, new uses and fundamental limitations of magnetic resonance imaging in cognitive scienceParkinson's Disease: The Mitochondria-Iron LinkMetals and NeurodegenerationUtility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disordersConverging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's diseaseExcessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease.Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.Defining a role for hemoglobin in Parkinson's diseaseNeuromelanin in parkinsonian disorders: an update.The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain.The Neuromelanin-related T2* Contrast in Postmortem Human Substantia Nigra with 7T MRIMidbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.Characterization of a Novel Monoclonal Antibody against Human Mitochondrial Ferritin and Its Immunohistochemical Application in Human and Monkey Substantia Nigra.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Redox Signaling in Neurotransmission and Cognition During Aging.Iron and dopamine: a toxic couple.Melanin and neuromelanin binding of drugs and chemicals: toxicological implications.In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.Calcium and Parkinson's disease.Bioavailable Trace Metals in Neurological Diseases.l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.Selective neuronal vulnerability in Parkinson disease.Alpha-synuclein and iron: two keys unlocking Parkinson's disease.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator.Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.Imaging of neuronal tissues by x-ray diffraction and x-ray fluorescence microscopy: evaluation of contrast and biomarkers for neurodegenerative diseases.Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Quantitative Susceptibility Mapping Reveals an Association between Brain Iron Load and Depression Severity.Bioactivity of Olive Oil Phenols in Neuroprotection.Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches.Parkinson's Disease Is Not Simply a Prion Disorder.Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain.Association of exposure to manganese and iron with striatal and thalamic GABA and other neurometabolites - Neuroimaging results from the WELDOX II study.Quantitative Susceptibility Mapping Reveals an Association between Brain Iron Load and Depression Severity.The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint.
P2860
Q26738375-DFBB1EA1-D7B9-46D9-9E41-F16C86F15925Q26746899-A5050992-BC59-42FC-ADAA-11D5B8A87501Q26752441-9B4CDBC6-944F-43A4-A2E4-CD673D81BEBBQ28066787-31B6EA8E-08A1-4780-8EEE-7133AA3FBA03Q28074143-7B6FF703-2BA0-4B0A-92F6-1630AF1F5EA6Q33767295-2F5B040E-9467-43B4-8BF7-2919BCC456B9Q33776138-FB0B4040-A5D6-410C-A064-372ABF3A12E5Q33917264-98C7C07A-FDBE-480D-B843-566C234FB872Q36359956-7FD484D5-96E1-4CAF-9030-E7520CE3F0EEQ36600664-101857E5-573C-4CC9-9471-F6F1B16D22C1Q37232653-F24F729F-6243-4340-8040-AC83F26A18B9Q37352812-13737F13-41E2-495E-A1E8-BCE6C280411EQ37703489-94B523C3-EA06-4766-AAD1-577AEA1BD20EQ37730855-165D686C-B9E2-4878-9552-132EE5428389Q38658203-8BB34A15-4CD7-40EA-9D7A-36A923B000CEQ38688126-693610F0-E0D5-4F1D-80E2-33915FFEF5BCQ38768061-F9BAD6DC-DCC4-4928-B299-073D7F88D76DQ38867426-3B10105E-C850-496F-B799-ADEF7A76F470Q38940194-31C1E684-D8BF-47B9-A17D-C84660308317Q38945252-CB3361C8-CA1D-4C93-B1CD-55D228E490B0Q38967236-52B2AB1D-CB42-408C-86D9-40830E5233CFQ39012371-0BB1D527-75F9-4DF5-9491-854807F4DC08Q39075112-45587B8C-22D6-4241-A6CE-D42AAAA61A9EQ39095738-ECFB2925-6509-4887-A004-BB035CEA9E71Q39123736-EE295945-A62C-400D-9F89-7730C121EE24Q39179797-F397C67F-A3CE-45DF-B420-1340FFD4FE68Q39282039-5A69D3B4-168D-4957-B204-6965FB9804A6Q39756769-DD41E5AB-7378-4487-BFBB-C1A1F3DF21F5Q39877122-FADB3C49-06FB-45A5-B46B-9CAE789E2200Q42639638-4771A969-B3E0-4E68-A05D-8A6C3F672A5FQ46311037-507493B6-AD0F-4347-B829-504AC1EF4D34Q46354756-EDB99A35-6191-44EB-B930-8AFD40322D82Q47093884-C69D0B22-22D4-409D-ADEE-51AA264B57CCQ47099956-DAC2C0DE-DAF0-4EAE-B016-C1302F09834BQ47183452-B294B0C2-04DD-4303-B766-DFE8025BBCB4Q47314960-2E8A161D-BAA1-4026-B107-AC09E8E72D34Q47614352-6F5C8B0B-3B59-4AAA-BC82-DC7D50A3C83AQ47743465-5CE55D75-082D-4A68-968E-DD0F525C4EE9Q47770760-83005E40-3351-459F-B1D1-D67B244B54C6Q47835285-4FAEB415-B02B-46BF-849F-943172164A46
P2860
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Interactions of iron, dopamine ...... aging and Parkinson's disease
@ast
Interactions of iron, dopamine ...... aging and Parkinson's disease
@en
Interactions of iron, dopamine ...... aging and Parkinson's disease
@nl
type
label
Interactions of iron, dopamine ...... aging and Parkinson's disease
@ast
Interactions of iron, dopamine ...... aging and Parkinson's disease
@en
Interactions of iron, dopamine ...... aging and Parkinson's disease
@nl
prefLabel
Interactions of iron, dopamine ...... aging and Parkinson's disease
@ast
Interactions of iron, dopamine ...... aging and Parkinson's disease
@en
Interactions of iron, dopamine ...... aging and Parkinson's disease
@nl
P2093
P2860
P50
P921
P3181
P1476
Interactions of iron, dopamine ...... aging and Parkinson's disease
@en
P2093
Luigi Casella
Luigi Zecca
Patricia Muñoz
P2860
P3181
P356
10.1016/J.PNEUROBIO.2015.09.012
P407
P577
2015-10-09T00:00:00Z